Biogen

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) is bringing its well-recognized Community Lab science learning program together with the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology to launch the new online Biogen-MIT Biotech in Action: Vir…

Shares of Biogen Inc. were down 0.3% in premarket trading on Monday after The New York Times reported on Sunday that a company event in late February led to "superspreading" of COVID-19 among its employees. Even after reports of positive tests among employees who attended the meeting came in, at le…

Shares of Vir Biotechnology Inc. gained 15% in premarket trading on Thursday after it said it intends to partner with Biogen Inc. to help develop and manufacture its monoclonal antibodies as a potential treatment of COVID-19. Biogen will handle clinical manufacturing of Vir's antibodies, the compa…

Biogen Inc. has ordered all of its workers to work from home until further notice, as part of a sweeping round of measures implemented after employees who attended a Boston management meeting tested positive for the coronavirus that causes COVID-19. Biogen had about 7,400 employees worldwide as of …

Biogen Blogs

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2020 financial results Wednesday, April 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA) Well-established safety profile and proven efficacy of SPINRAZA in a broad range of patients supports exploration of the higher dose Biogen

Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously

The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world. As governments, businesses and other organizations take unprecedented measures to help mitigate the spread of the outbreak, we want to reinforce our deep commitment to our employees, our

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed